Table 1.
Characteristic | Category | Cases N = 3628 |
Controls N = 5126 |
||
---|---|---|---|---|---|
N | % | N | % | ||
Study type | Population-based or cohort | 2439 | 67.2 | 3895 | 76.0 |
Hospital-based | 1189 | 32.8 | 1231 | 24.0 | |
Age (years) | < 50 | 432 | 11.9 | 553 | 10.8 |
50–59 | 1150 | 31.7 | 1462 | 28.5 | |
≥ 60 | 2046 | 56.4 | 3111 | 60.7 | |
Parity | Nulliparous | 431 | 12.1 | 582 | 11.5 |
Parous | 3141 | 87.9 | 4459 | 88.5 | |
Unknown | 56 | 85 | |||
Menopausal status | Pre-menopausal | 540 | 15.0 | 878 | 17.4 |
Post-menopausal | 3058 | 85.0 | 4194 | 82.6 | |
Unknown | 30 | 54 | |||
Postmenopausal HT use in post-menopausal women | Ever | 1737 | 59.6 | 2116 | 57.4 |
Never | 1179 | 40.4 | 1568 | 42.6 | |
Unknown | 142 | 510 | |||
BMI (kg/m2) | < 25 | 1542 | 42.9 | 2095 | 41.3 |
≥ 25 | 2049 | 57.1 | 2982 | 58.7 | |
Unknown | 37 | 49 | |||
Family history breast cancer in first degree relatives | No | 2808 | 81.5 | 3944 | 85.1 |
Yes | 637 | 18.5 | 688 | 14.9 | |
Unknown | 183 | 494 |
HT hormone therapy